课题基金 / 基金详情

Pioneering a novel cancer targeting glyco-immunotherapy strategy

Pioneering a novel cancer targeting glyco-immunotherapy strategy
开创了一种新型癌症靶向糖免疫治疗策略
批准号:
2889867
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Background: Human cells are coated in a thick layer of sticky sugars called the glycocalyx. Uniquely cancer cells are covered with an excess of the human 'sialic acid' sugar Neu5Ac, and this has been shown to 'camouflage' the cells from the immune system. However, 2 million years ago a hydroxylated form of this sugar known as Neu5Gc was also present on human cells, but evolutionary selection drove inactivation of the gene required for conversion of Neu5Ac to an ancestral sialic acid, and this resulted in the loss of the ancestral sugar from the surface of human cells. Following this selection event, humans have developed circulating antibodies against this sugar. Objectives: The aim of the project is to resurrect this ancestral sugar specifically in prostate cancer cells using antibody-targeted gene delivery. This strategy would aim to unleash the immune system's existing antibodies to kill the cancer cells, constituting a completely novel approach to cancer immunotherapy. Experimental approach: Using novel chemical glyco-biology methods1,2 the student will contribute to the design of prostate cancer-cell specific gene delivery systems. The functional activity of these tools will be tested on well-established Prostate cancer (PCa) cell-lines, using a combination of flow cytometry, glycan mass spectrometry and immunofluorescence to determine the extent of cell surface glycan reengineering. Validation of the best delivery system will then follow using in vitro culture of primary prostate-isolated tumour cells and spheroids. This is a cross-disciplinary project primarily based at the University of York in the labs of Dr Martin Fascione (https://www.york.ac.uk/chemistry/staff/academic/d-g/mfascione/; Chemistry) and Dr Nathalie Signoret (https://www.york.ac.uk/biology/research/molecular-cellular-medicine/signoret/; Immunology, Hull York Medical School), and working collaboratively with Prof Craig Robson (https://www.ncl.ac.uk/medical-sciences/people/profile/cnrobson.html; Newcastle University Centre for Cancer). The student will train in aspects of organic chemistry, immunology and cancer cell biology specifically developing skills in glycoscience, protein bioconjugation, molecular biology, advanced cell imaging techniques and flow cytometry. The project would suit a candidate with an interest in translational science and any of chemical biology, glycoscience, immunology and/or cancer biology.Novelty and Timeliness: In the last decade treatment of cancer has been revolutionised by antibody delivery of small molecule drugs and subsequently by cancer immunotherapy strategies which coopt the patient's own immune system to fight the cancer. For the first time we aim to harness aspects of both these field defining strategies simultaneously through re-engineering of cell surface glycans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: